Renato Mantegazza

Impact of Ravulizumab on Patient Outcomes and Quality of Life in Generalized Myasthenia Gravis

C. Antozzi, Renato Mantegazza, 2023, Patient related outcome measures.

Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis

A. Singleton, J. Lamb, F. Mastaglia, 2016, Neurobiology of Aging.

Efficacy, Safety, and Tolerability of Efgartigimod in Patients With Generalized Myasthenia Gravis: Analysis of the Phase 3 ADAPT Study (4520)

C. Karam, K. Utsugisawa, P. Ulrichts, 2021, Neurology.

COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)

H. Wiendl, M. Maas, J. Vissing, 2020, The Lancet Neurology.

Efficacy of ravulizumab in patients with generalized myasthenia gravis by time from diagnosis: A post hoc subgroup analysis of the CHAMPION MG study.

H. Kushlaf, Renato Mantegazza, Tuan Vu, 2024, Muscle & nerve.

Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study

Melissa Brock, R. Nowak, M. Vanderkelen, 2024, Therapeutic advances in neurological disorders.

Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis.

M. Katsuno, Djillali Annane, Renato Mantegazza, 2022, NEJM evidence.

Efgartigimod improves triple-negative myasthenia gravis.

Elena Rinaldi, R. Frangiamore, C. Antozzi, 2023, Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology.